Drl

Dr Reddy’s area of focus in the domestic market includes hepatology, diabetic nutrition and its health-tech platform

Ideas for profit | Dr Reddy’s: COVID opportunity key growth lever

Dr Reddy’s strong product pipeline is suitably supported by R&D & capex budget. In FY22, product launch momentum is expected to remain strong. Another emerging growth lever for DRL are China, India & Europe opportunities. Given emerging earnings catalysts, Dr Reddy’s remains an accumulation opportunity on declines.

In a major win for Dr Reddy’s, US court allows sale of generic Suboxone film

Rejecting arguments by Indivior, the judge left in force a ruling that allows DRL to put the generic drug on the market as early as February 20

Dr Reddy’s plummets 23% as Jefferies red flags ‘repeat’ observations

According to a CNBC-TV18 report, Jefferies, in its research note, has said that the Form 483 issued by US Food and Drug Administration (US FDA) contains four repeat observations out of the total 11 observations.

Pharma: Here's what all happened in the sector last week

Here's what happened in pharma last week

DRL says no claims for monetary damages in US patent case

Drug major Dr Reddy's Laboratories had received an unfavourable ruling in a US court regarding a patent infringement case over anti-nausea injection Aloxi.

Good Q3 but Dr Reddy's still far from sustainable growth: Expert

Surajit Pal, Research Analyst at Prabhudas Lilladher, said the pharma sector is undergoing a transition and all the large midcaps will underperform.

See Nuvaring opportunity for Dr Reddy's in Q4FY18: Credit Suisse

Nuvaring is the largest of the eight products that Dr Reddy's has bought from Teva in June 2016. DRL acquired a portfolio of eight abbreviated new drug applications (ANDAs) in the US for USD 350 million as part of the divestment process in Teva's acquisition of Allergan's generic business.

New guidelines to cut approval time of biosimilars in half

Priya Sheth of CNBC-TV18 reports that the regulator plans to categorically outline aspect of post-marketing safety of drugs. These new regulations may cut approval timeline by more than half for biosimilars.

Sensex, Nifty under pressure; Dr Reddy's jumps 3%, SBI falls

Bank of Baroda (-7 percent), SBI (-3 percent), Bharti Airtel (-3 percent) and GAIL (-2 percent) were the big losers in the Nifty. Other laggards in the index were Axis Bank (-1 percent),BPCL (-1 percent),Hero Motocorp (-1 percent) and Adani Ports (-1 percent).

Dr Reddy's ink pact with Purdue varsity for drug research

According to a statement issued by the University, the intent of the MoU is to forge a strong strategic partnership in a range of research areas and novel technologies in the field of pharmaceutical processes and product development.

Accumulate Dr Reddys Labs; target of Rs 3957: KRChoksey

KRChoksey is bullish on Dr Reddys Laboratories (DRL) and has recommended accumulate rating on the stock with a target price of Rs 3957 in its research report dated May 13, 2015.

Buy Dr Reddys Laboratories; target of Rs 3878: Angel

Angel Broking is bullish on Dr Reddys Laboratories (DRL) and has recommended buy rating on the stock with a target of Rs 3,878 in its February 02, 2015 research report.

Dr Reddy's launches antibiotic drug in US market

Avelox (moxifloxacin HCl) tablets had a sales figure of approximately USD 195 millions in 2013: IMS Health

Mkt will keep eye on RBI commentary on inflation: Religare

Tirthankar Patnaik, Director - Institutional Research, Religare Capital Markets believes if the US Federal Reserve does not move on taper today, market will resume uptrend. He feels the actual tapering will start only in March.

Buy Dr Reddys Laboratories, says Sukhani

One can buy Dr Reddys Laboratories, says Sudarshan Sukhani of s2analytics.com. "When the Nifty corrected 250 points, DRL consolidated. This consolidation probably could easily breakout today," he adds.

BSE Sensex gains; tech drags, Cipla & DRL up over 2%

Realty, banking, capital goods, oil and gas were supporting the index.

Nifty flirts with 6000; DRL falls 2.1%, Eicher up 6.9%

The Sensex was up 67.24 points at 19758.91 while the Nifty gained 27.60 points to be at 6008.05. GAIL, Bharti Airtel, Tata Motors, ONGC and Hindalco were the key gainers in the Sensex.

Nifty stuck at 6000; oil stocks rally, Aptech surges 9%

Strength in oil stocks was supporting the indices. The Sensex was up 103.56 point at 19795.23 while the Nifty gained 35.45 points to be at 6015.90.

Dr Reddy's Lab appoints GV Prasad as chairman

Pharma company Dr Reddy's Laboratories Ltd Monday said it has appointed GV Prasad as chairman and CEO, and Satish Reddy as cice chairman.

Anji Reddy passes away

K Anji Reddy, promoter and chairman of the country's second largest drug maker Dr Reddy's Laboratories, passed away today. Reddy was 73-year-old and is survived by a son and a daughter.

Hold Dr Reddys Laboratories: Ventura Securities

Ventura Securities has recommended hold rating on Dr Reddy Laboratories (DRL), in its February 21, 2013 research report. The research firm, expects company's performance in FY14 to remain muted and restricted to single digit growth.

DRL gains for sixth day, Morgan Stanley says overweight

Healthcare firm Dr Reddy's Laboratories gained for the sixth consecutive session on Friday, rising more than four percent in six days.

Stocks in news: Chettinad Cement, GMR, Suzlon, DRL

Chettinad Cement | GMR | Maruti | Suzlon | L&T | Dr Reddy's Labs | Union Bank of India | Bharti Airtel and Tata Steel are stocks, which are in the news today.

Bristol-Myers sues DRL for patent infringement in US

US-based drug maker Bristol-Myers Squibb Company has filed patent infringement case against Dr Reddy's Laboratories (DRL) over the cancer drug Ixempra.